Research Article

Adapting antibodies for clinical use.

BMJ 1992; 305 doi: https://doi.org/10.1136/bmj.305.6865.1348 (Published 28 November 1992) Cite this as: BMJ 1992;305:1348
  1. R. E. Hawkins,
  2. M. B. Llewelyn,
  3. S. J. Russell
  1. Medical Research Council Centre, Cambridge.

    Abstract

    Techniques for antibody engineering are now overcoming the problems that have prevented monoclonal antibodies being used routinely in clinical practice. With chemical and genetic manipulation antibodies can be linked to bacterial toxins, enzymes, radionuclides, or cytotoxic drugs, allowing targeting of treatment. Antigen binding sites from antibodies raised in mice can be jointed with human IgG to reduce immunogenicity. In vitro gene amplification and genetic engineering of bacteriophage have produced large antibody gene libraries and facilitated large scale production of human monoclonal antibodies with high specificity. The trickle of monoclonal antibodies into clinical practice may soon become a flood.